Trial Profile
A phase I clinical trial of intratumourally administered reovirus monotherapy in patients with T2 prostate cancer.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Nov 2010
Price :
$35
*
At a glance
- Drugs Pelareorep (Primary)
- Indications Prostate cancer
- Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
- 05 Nov 2010 New trial record.
- 27 Feb 2004 Final results presented in an Oncolytics Biotech media release.
- 31 Mar 2003 Interim results presented in an Oncolytics Biotech media release.